secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0000950170-24-039286
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa ends FY2023 with $88.5M cash; two Phase 2 studies fully enrolled, data due H2 2024
--------------------------------------------------------------------------------

- Cash and equivalents $88.5M as of Dec 31, 2023; no debt outstanding.
- Operating expenses $31.4M in 2023, up $3.7M from $27.7M in 2022.
- Phase 2 Karisma-Endoxifen (breast density) fully enrolled Nov 2023; top-line data expected H2 2024.
- Phase 2 I-SPY 2 (neoadjuvant breast cancer) fully enrolled Feb 2024; data expected H2 2024.
- First patient dosed in Phase 2 RECAST DCIS study; EVANGELINE data at AACR April 9, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000095017024039286/0000950170-24-039286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000095017024039286/atos-20240401.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-039286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer